Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL's Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years of Age.

NCT02212106 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT02212106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02212106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL's Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years of Age.
Lead sponsor
Seqirus
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2014
Enrollment
402 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human